Supplementary Table 1.
Characteristics of IBD Patients Receiving SARS-CoV-2 Additional Vaccine by Response to Initial Vaccine Series
| All patients (n = 659) | Detectable initial antibody (n = 612) | Undetectable initial antibody (n = 47) | P value | |||
|---|---|---|---|---|---|---|
| Age, y, means (SD) | 44.6 (14.4) | 44.6 (14.5) | 44.6 (13.8) | .999 | ||
| Female, n (%) | 475 (72) | 443 | (72) | 32 | (68) | .527 |
| Disease type, n (%) | ||||||
| Crohn’s disease | 476 (72) | 439 | (72) | 37 | (79) | |
| Ulcerative colitis/IBD-unclassified | 177 (27) | 167 | (27) | 10 | (21) | |
| Type of vaccine (initial), n (%) | <.001 | |||||
| BNT162b2 | 415 (63) | 381 | (62) | 34 | (72) | |
| mRNA-1273 | 243 (37) | 228 | (37) | 10 | (21) | |
| Ad26.COV2.S | 5 (1) | 2 | (0) | 3 | (6) | |
| Type of vaccine (additional), n (%) | .131 | |||||
| BNT162b2 | 415 (63) | 379 | (62) | 36 | (77) | |
| mRNA-1273 | 243 (37) | 232 | (38) | 11 | (23) | |
| Ad26.COV2.S | 1 (0) | 1 | (0) | 0 | (0) | |
| Medication treatment at baseline vaccination, n (% yes)a | ||||||
| No medical therapy | 15 (2) | 13 | (2) | 2 | (4) | .345 |
| Systemic steroids | 36 (5) | 31 | (5) | 5 | (11) | .105 |
| Anti-TNF monotherapy | 274 (42) | 258 | (42) | 16 | (34) | .277 |
| Anti-TNF combination therapyb | 121 (18) | 101 | (17) | 20 | (43) | <.001 |
| Thiopurine | 58 (9) | 56 | (9) | 2 | (4) | .254 |
| Methotrexate | 5 (1) | 5 | (1) | 0 | (0) | .534 |
| Mesalamine or sulfasalazine (any) | 118 (18) | 114 | (19) | 4 | (9) | .081 |
| Budesonide | 26 (4) | 22 | (4) | 4 | (9) | .095 |
| Vedolizumab | 72 (11) | 72 | (12) | 0 | (0) | .013 |
| Ustekinumab | 92 (14) | 90 | (15) | 2 | (4) | .046 |
| Tofacitinib | 11 (2) | 10 | (2) | 1 | (2) | .799 |
NOTE. Detectable initial antibody was defined as the quantitative measurement of anti–receptor binding domain IgG antibodies specific to SARS-CoV-2 using the LabCorp Cov2Quant IgG assay with results of ≥1.0 μg/mL.
IBD, inflammatory bowel disease; mRNA, messenger RNA; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; TNF, tumor necrosis factor.
a
Numbers do not add to total n because patients may be taking more than 1 medication class.
b
Including azathioprine, 6-mercaptopurine, or methotrexate.